StockData

CNS Pharmaceuticals vs Monopar Therapeutics

CNSP and MNPR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNSP and MNPR compare

Monopar Therapeutics is the larger company, worth 114 times as much as CNS Pharmaceuticals ($483M against $4.2M).

Monopar Therapeutics scores higher on the StockData Score (7 against 5 for CNS Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNSPMNPR
Size and price
Market cap$4.2M$483M
Share price$2.89$72.00
Change, 1 year−56.1%−12.8%
Change, 5 years−100.0%206%
Beta (5Y)1.630.78
Employees822
StockData Score
Total score57 (better)
Valuation score1 (better)0
Growth score00
Performance score01 (better)
Health score46 (better)
Dividend score00
Valuation
P/B0.2× (better)3.8×
Profitability
Return on equity−107%−15.3% (better)
Financial health
Debt / equity0.000.00
Interest coverage−1131.6×–
Current ratio5.8643.55 (better)
Altman Z-score−7.7590.53 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions19.2%92.7%
Held by insiders26.5%–
Insider net buying, 12 months$44.0K (better)−$5.6M
Short interest, % of float0.15%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.